Navigation Links
Delpor Selected by the NIH to Exhibit its Technology at the 2017 BIO International Convention
Date:5/31/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that it has been selected by the National Institutes of Health (NIH) to exhibit and showcase its technology at the upcoming International Convention of the Biotechnology Innovation Organization (BIO). The Convention will take place in San Diego, CA on June 19-22, 2017. Delpor will be exhibiting at BIO’s “Innovation Zone” along with other innovative companies.

“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners,” said Tassos Nicolaou, President and CEO of Delpor.

During the conference, Delpor expects to focus on its lead program, DLP-114 (6-month risperidone formulation for schizophrenia maintenance treatment) and on its two key implantable drug delivery technologies (PROZOR™ and NANOPOR™).

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at http://www.delpor.com.

About DLP-114
Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 6 months. Additional features are expected to include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/DelporToExhibitat2017Bio/InnovationZone/prweb14380665.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the Treatment of Schizophrenia
2. Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
3. Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
4. SimpleTrials Selected as a Top 10 eClinical Trial Management Solution Provider by Pharma Tech Outlook
5. NewTechBio Selected to Provide Aquatic Remediation Solution to Algae Infested Savannah River Site Experiencing High PH and Phosphorus
6. Inflamax Research selected to join Ontario Premier Kathleen Wynne’s trade mission to Israel
7. Proove CEO and Founder Brian Meshkin Selected as a Finalist for the ACG 21st Annual Awards
8. Pioneering biomedical company selected for Shinzo Abe's “Bridge of Innovation” Initiative
9. Nanotechnology expert selected to lead OHSUs large-scale early cancer detection initiative
10. Apervita Selected by GE Healthcare to Help Expand its Advanced Analytics Footprint
11. AlgaEnergy Selected to Present at CleanEquity Monaco 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2018)... Tenn. (PRWEB) , ... November 05, 2018 , ... ... radiology and telemedicine company backed by Siemens Healthineers and several healthcare VC firms ... based radiology solution and making a history by purchasing tokens and obtaining its ...
(Date:10/31/2018)... ... October 30, 2018 , ... Rooam , the premier payment platform ... this winter. After its acquisition of the Tally payment app, the leading payment platform ... tips, Rooam will grow its market share and increase the number of restaurant and ...
(Date:10/29/2018)... LOUIS (PRWEB) , ... October 29, 2018 , ... ... healthcare employers nationwide, released its schedule of physician career fairs planned for 2019. The ... and will focus hosting live events in the areas of the country which have ...
(Date:10/24/2018)... SAN JOSE, Calif. (PRWEB) , ... October 23, ... ... and cell biology technologies, today announced a new, exciting brand for its recently ... technology platform with Molecular Devices’ Biologics Biotherapeutics portfolio of products, and henceforth will ...
Breaking Biology Technology:
(Date:11/16/2018)... , ... November 16, 2018 , ... ... P.G., was awarded the International Bottled Water Association’s (IBWA’s) IBWA/Shayron Barnes-Selby Advocacy Award ... IBWA’s Advocacy Award, named “The Selby” after longtime IBWA contributor Shayron Barnes-Selby, is ...
(Date:11/15/2018)... ... November 14, 2018 , ... Researchers at the ... up the analysis and publication of biomedical data from many months or years ... now, the primary method available to share biomedical research data has been through ...
(Date:11/13/2018)... LINDA, Calif. (PRWEB) , ... ... ... (HRAM) mass spectrometers (MS) are a class of MS instrumentation with capability ... measuring their accurate masses. Specifically, those coupled to liquid chromatograph (HRAM LC/MS) ...
Breaking Biology News(10 mins):